|
View an In-Depth Analysis of Emerging and Rapidly Growing ADME/Tox Screening Technologies
Research and Markets (researchandmarkets.com/reports/c35555) has announced the addition of Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies to their offering.
Dublin (PRWEB) April 13, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c35555) has announced the addition of Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies to their offering.
Researchers in the pharmaceutical and biotech industry have been developing tools over the years to maximize the efficacy of drugs while minimizing toxicity, and advances have been made. A decade ago, the number of drugs failing preclinically due to poor pharmacokinetics was upwards of 40%, but improved in vitro and animal models have reduced that rate to about 10%. Failures due to ADME and toxicology, however, are still in the 50% to 60% range, making it the number one reason for preclinical attrition. That disparity is likely due to outdated tools, says "Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products," a white paper published last year by FDA: "Despite some efforts to develop better methods, most of the tools used for toxicology and human safety testing are decades old. Although traditional animal toxicology has a good track record for ensuring the safety of clinical trial volunteers, it is laborious, time-consuming, requires large quantities of product, and may fail to predict the specific safety problem that ultimately halts development."
The white paper noted that one pharmaceutical company estimated that clinical failures based on liver toxicity cost them more than $2 billion over the last decade. Measuring the ADME/Tox properties early can be one method of minimizing failure. The process of drug discovery and development requires that a drug’s behavior in the human body is modelled in other systems before being actually tested in humans. When considering the drug discovery process backwards, certain toxicities must be determined before long-term use is allowed. Prior to this, the correct starting dose for human tests must be estimated. This over simplification illustrates some of the reasons for the processes being analysed with ADME and toxicology for most drugs.
This report provides an in-depth analysis of emerging and rapidly growing ADME/Tox screening technologies. The report focuses on emerging technologies, market drivers, restraints, challenges, and provides in-depth company profiles and key market engineering parameters for in vitro and in silico ADME/Tox screening markets.
Chapters are as follows:
Executive Summary
Chapter 1 Introduction to predictive ADME/Tox screening
Chapter 2 Traditional methods of ADME/Tox testing
Chapter 3 Novel in vivo and in vitro predictive models
Chapter 4
In silico predictive models
Chapter 5 Appendix
Index
List of Figures
List of Tables
Companies Mentioned:
- Aclara Biosciences
- Advion Biosciences
- Agilent Technologies
- Amphioxus Cell Technologies
- Applied Biosciences
- BD Biosciences
- BioTrove Inc.
- Caliper Life Sciences
- Covance
- DanioLabs
- Eksigent Technologies
- Gene Logic
- Hurel Corporation
- LGC Limited
- Nanostream Inc.
- NemaRx Pharmaceuticals Inc.
- Nimbus Biotechnology
- Novascreen
- Perkin Elmer
- Phylonix
- Qualyst
- Tecan
- Thermo Electron Corp.
- Xenogen
- Zygogen
- Zyomyx
- Accelrys
- Applied Biosystems
- Aureus Pharma
- BG Medicine
- BioByte Corporation
- BioKin Limited
- Bio-Rad Laboratories
- ChemSilico
- Chenomx
- ComGenex Inc.
- CompuDrug
- Cyprotex
- Elsevier MDL
- GeneGo
- Leadscope
- LHASA Limited
- Molecular Discovery Ltd.
- Pharma Algorithms
- Simulations Plus
For more information visit http://www.researchandmarkets.com/reports/c35555
Source: Business Insights
Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980
###
|
